论文部分内容阅读
目的探讨CD40在弥漫大B细胞淋巴瘤(DLBCL)中的表达及临床意义。方法采用免疫组化检测186例DLBCL组织中CD40的表达及平均密度(IOD/AOI),以IOD/AOI平均值为阈值,分为高表达组(IOD/AOI≥94.06±4.21,89例)和低表达组(IOD/AOI<94.06±4.21,97例)。分析CD40的表达与患者临床特征及预后的关系。结果CD40阳性表达率为70.4%(131/186)。CD40的表达与年龄、性别、临床分期、乳酸脱氢酶以及国际预后指数评分无明显相关性(P>0.05)。高表达组患者的生存率高于低表达组(P<0.05)。结论 CD40的表达可作为判断DLBCL患者预后的标志。
Objective To investigate the expression of CD40 in diffuse large B cell lymphoma (DLBCL) and its clinical significance. Methods The expression of CD40 and the average density (IOD / AOI) of 186 cases of DLBCL were detected by immunohistochemistry and divided into high expression group (IOD / AOI≥94.06 ± 4.21, 89 cases) and IOD / AOI Low expression group (IOD / AOI <94.06 ± 4.21, 97 cases). To analyze the relationship between the expression of CD40 and the clinical characteristics and prognosis of patients. Results The positive rate of CD40 expression was 70.4% (131/186). There was no significant correlation between the expression of CD40 and age, gender, clinical stage, lactate dehydrogenase and international prognostic index (P> 0.05). The survival rate of high expression group was higher than that of low expression group (P <0.05). Conclusion CD40 expression can be used as a marker to judge the prognosis of DLBCL patients.